Search

everythinglearnresearchcommunity

for

Search:↓

The protein p21 is more abundant in normal skin cells than in melanoma cells and may help protect against melanoma, with UVB light affecting its levels.

Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.

No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.

JAK inhibitors can help regrow hair in alopecia areata but have potential long-term risks and require careful monitoring.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

TNF-inhibitor induced alopecia can be treated effectively with different therapies.

Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.

Co-trimoxazole may help treat autoimmune diseases.

Amivantamab can cause severe skin eruptions and scarring, requiring drug discontinuation and early treatment.

Iressa often causes skin issues like acne and dryness in lung cancer patients.

Ustekinumab significantly improved sexual function and quality of life for people with moderate to severe psoriasis.

Dupilumab for atopic dermatitis can cause mild skin issues in some patients.

A pilomatrixoma in the eyebrow can cause hair loss and skin lightening.

JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.

Imatinib can cause hair loss due to lichen planopilaris.

Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.

The treatment improved survival and controlled cancer spread but required managing side effects like rashes.

Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.

Targeting the IL-23/IL-17 pathway effectively treats several inflammatory skin diseases.

Cutaneous lupus patients have higher levels of certain immune cells in their blood and skin.

ISCK03 stops melanin production in human melanoma cells and lightens skin color in mice and guinea pigs.

Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.

Upadacitinib successfully treated a child's severe skin and hair loss issues.

Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.

PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.

Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.

Ruxolitinib cream shows promise for vitiligo, and early melanoma diagnosis is crucial.

Upadacitinib may cause hair loss.

A new microneedle patch significantly improves melanoma treatment by using a special material to activate cancer-fighting drugs and disrupt cancer cells.

Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.